[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [RiskMitigation](https://github.com/mm80843/T3.5/tree/main/docs/RiskMitigation/index.md) >> Individual ID:PBN__RiskMitigation_1863 

# __Conduct more efficacy studies in clinical settings to evaluate the impact of these measures on TB transmission__

## Category to which it belongs

* [Promote comprehensive testing and tracing, prioritize vulnerable populations, reduce diagnosis-to-surgery time, recognize stress symptoms, and improve testing accuracy.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_344.md)

## Closest similar item

* [Conduct further research and studies on the effectiveness of UVGI in preventing tuberculosis transmission](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2324.md)
* [Promote awareness about asymptomatic transmission, encourage individuals to practice preventive measures regardless of symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2315.md)
* [Combined use of WBE followed by clinical testing](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1206.md)
* [Improve vaccine efficacy through research and development.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2512.md)
* [Evaluate efficacy differences based on symptoms](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_1187.md)
* [Conduct comparative studies on disease severity between re-infected and initially infected patients.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2515.md)
* [Conducting research studies and gathering quantitative data on the outcomes and effectiveness of UBPI.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2920.md)
* [Increase testing capacity to include testing of mild or asymptomatic individuals to obtain a more accurate assessment of the prevalence.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2563.md)
* [Evaluate the difference in efficacy between symptomatic and asymptomatic individuals.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2516.md)
* [Improve reporting standards and conduct high-quality research studies on preventive interventions.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2071.md)

## Risks possibly mitigated by this Mitigation

* [Absence of efficacy studies in clinical settings](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1367.md)

